MBMangesh Bhide

Mangesh Bhide

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mangesh Bhide has a total of 370 co-authors. Here are the top co-authors by number of shared publications:

  • Katarína Bhide

    Laboratory of biomedical microbiology and immunology, University of veterinary medicine and pharmacy in Kosice, Kosice, Slovakia

    17 shared publications
  • Elena Bencurova

    Department of Bioinformatics, University of Würzburg, Würzburg, Germany

    14 shared publications
  • Lucia Pulzova

    Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Kosice, 041 81 Kosice, Slovakia

    13 shared publications
  • Amod Kulkarni

    Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Kosice

    9 shared publications
  • Patrícia Petroušková

    Department of Epizootiology, Parasitology and Protection of One Health, University of Veterinary Medicine and Pharmacy in Kosice, Komenskeho 73, 041 81 Kosice, Slovakia

    9 shared publications
  • Zuzana Tkáčová

    Laboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy in Kosice, Kosice, Slovakia

    8 shared publications

Latest Publications

  • Open Access

    Anti-SARS-CoV-2 VHH and C7C peptide fused with Angiopep-2 efficiently traverse blood-brain barrier model and neutralizes virus

    by Mangesh Bhide, Katarina Bhide, Evelina Mochnacova, Jakub Viglasky, Diana Kosturikova, Amod Kulkarni

    Introduction: The therapy for SARS-CoV-2-related CNS infection relies on treating neuroinflammation and associated damage, rather than a specific antiviral. The lack of specific antiviral therapeutics is mainly attributed to the limited permeability of drugs across the blood-brain barrier. Methods: In this paper, we present a detailed pipeline for selecting VHHs (single variable domain of llama heavy chain antibody) and 7-mer cyclic peptides (C7C) from phage-display libraries that bind to the spike protein and SARS-CoV-2 virion. Soluble VHH and C7C peptides overexpressed in the E. coli SHuffle Express, which enables the formation of the disulfide bond essential for proper VHH and C7C folding and function, were purified and rigorously tested for their capacity to neutralize pseudovirus, cell toxicity, hemocompatibility, etc. The best VHH and C7C candidates with favorable attributes were then fused with the CNS-homing peptide Angiopep-2 and thoroughly assessed for the ability to neutralize the virus along with other safety attributes mentioned earlier. Results and discussion: The best VHH and C7C candidates, VHH E12 and C7C 18 , tested for their ability to neutralize live virus in a plaque reduction neutralization test, showed EC 50 0.045 μg/mL and 0.01 μg/mL, respectively. Both VHH E12 and C7C 18 , however, fail to cross the blood-brain barrier in vitro, thus were fused with CNS-homing peptide Angiopep-2. VHH E12 -Angiopep-2 and C7C 18 -Angiopep-2 fusion constructs showed increased crossing across the blood-brain barrier by 5.4-fold and 11.2-fold, respectively, while maintaining their ability to neutralize the virus. Molecules generated here, particularly C7C 18 -Angiopep-2, hold merit for further in vivo testing and preclinical studies.


  • Top Cited Papers
    Open Access

    SARS-CoV-2 nucleocapsid protein forms complexes with soluble complement regulatory proteins that can bind to the virion

    by Jakub Víglaský, Katarína Bhide, Lea Talpasova, Ľubica Fialová, Mangesh Bhide

    The SARS-CoV-2 nucleocapsid protein has been detected in the plasma of COVID-19 patients, and its levels in the plasma correlate with the severity of the disease. It is also an immunomodulatory protein, triggering the release of proinflammatory cytokines. Complement system dysregulation in COVID-19 patients led us to hypothesize that either nucleocapsid protein or spike protein might interact with the proteins of the complement system, mainly complement regulatory proteins (CRPs). We demonstrate that the nucleocapsid protein, but not the spike protein, binds to multiple CRPs, including C1-inhibitor, C4-binding protein, factor H, and vitronectin. The nucleocapsid protein binds to both the recombinant spike protein and the SARS-CoV-2 virions. We further demonstrated that the virion-nucleocapsid-CRP complex could be formed. Recruitment of the CRPs on SARS-CoV-2 virion mediated by nucleocapsid protein deserves further investigation to reveal complement modulation strategies of SARS-CoV-2.


  • Open Access

    Comprehensive mapping of the signaling events evoked by SARS-CoV-2 variants delta and omicron in human astrocytes

    by Katarina Bhide, Monika Slavikova, Lea Talpasova, Katarina Kuckova, Boris Klempa, Punit Tyagi, Mangesh Bhide

    COVID-19 causes a wide range of complications in the central nervous system, including encephalitis and other neurological symptoms such as memory problems, psychological disorders, depression, and anxiety. We present comprehensive data on the changes in gene expression levels in astrocytes infected with the Delta or Omicron variants of SARS-CoV-2. In RNA-seq data, we found 346 genes that were significantly evoked (197 up- and 149 down-regulated) in astrocytes challenged with the Omicron variant, compared to 341 evoked genes (215 up- and 126 down-regulated) in the Delta variant. A surprisingly large number of genes were exclusively evoked by Delta (82 up- and 48 downregulated) and Omicron variants (65 up and 60 downregulated). Numerous pathways, including those pertaining to the neuronal system, metabolism, response to viral infection, signal transduction, cytokine signaling, and homeostasis, were dysregulated in infected astrocytes. In this report we have dissected major pathways that are related to pathogen recognition, integrity of the BBB and glia limitans, and neurological disorders that could lead to neurological symptoms listed above. Our findings also reveal dysregulation of a large number of non-coding RNAs. The data presented here may help us better understand the role of astrocytes in the neurological disorders seen in COVID-19 patients.


  • Open Access

    Nanobody conjugated with dendrimer nanoparticles effectively neutralizes tick-borne encephalitis virus

    by Jana Jozefiaková, Amod Kulkarni, Dinesh Dhumal, Ádám Kevély, Eva Nováková, Kamila Koči, Ling Peng, Juraj Koči, Mangesh Bhide

    Tick-borne encephalitis virus (TBEV) is a neurotropic flavivirus causing severe meningitis, encephalitis, or meningoencephalitis. The blood-brain barrier (BBB) prevents therapeutic agents from reaching the brain; therefore, specific antiviral therapy that can cross the BBB and treat TBEV-induced infection is urgently needed. In this study, nanobodies (NBs) targeting domain III (DIII) of the envelope (E) glycoprotein of TBEV were developed and conjugated to drug delivery nanosystems based on self-assembling dendrimer nanomicelles (DNs) and gold nanoparticles (AuNs) to facilitate BBB passage and viral neutralization. NBs were derived from the variable region of heavy chain-only llama antibodies and panned against DIII using phage display. The most active NBs were conjugated with DNs and AuNs. Remarkably, the dendrimer nanosystem decorated with the nanobody clone TA3 (TA3-DNs) and the peptide Angiopep-2 effectively crossed the BBB model and neutralized TBEV. Therefore, TA3-DNs constitute a promising candidate for treating TBEV, and merit further validation in animal models for future translational studies.


  • Open Access

    Peptides developed against receptor binding sites of the E glycoprotein neutralize tick-borne encephalitis virus

    by Patrícia Petroušková, Katarína Bhide, Evelína Mochnáčová, Amod Kulkarni, Jana Jozefiaková, Zuzana Tkáčová, Tomáš Maľarik, Katarína Kucková, Lea Talpašová, Jakub Víglaský, et al.

    Infection caused by tick-borne encephalitis virus (TBEV) often manifests with meningitis or encephalitis. Domain III (DIII) of the envelope (E) glycoprotein on the TBEV surface facilitates virion attachment to the cell receptor and initiates cell entry. As a result, this research focused on the DIII to develop antiviral molecules that could prevent cell entry. We first identified two receptor-binding sites (RBS, 300SGLTYTMCDK309 and 317APTDSGHDTVVMEVTFSGTKPCR339) on DIII, that are involved in binding to human brain microvascular endothelial cells (hBMECs). Then we sought to isolate peptides from two combinatorial peptide-phage libraries that bind to the RBS and prevent protein E from attaching to hBMECs. Three cyclic peptides (CP2-CNSSKLHMC, CP20-CDGRPDRAC, CP23-CMKESIRGC) and a linear peptide (LP16-AFHPRQMETQMY) inhibited DIII binding to hBMECs. CP2 and CP20, both non-cytotoxic and hemocompatible, effectively neutralized a live virus. CP2 and CP20 deserve further attention for their potential application as anti-TBEV therapeutics that prevent viral cell entry.


  • Open Access

    Antimicrobial cyclic peptides effectively inhibit multiple forms of Borrelia and cross the blood-brain barrier model

    by Evelína Mochnáčová, Katarína Bhide, Katarína Kucková, Jana Jozefiaková, Tomáš Maľarik, Mangesh Bhide

    Infection caused by neuroinvasive Borrelia often manifests long-term CNS disorders and is difficult to treat as most antibiotics fail to attain an effective concentration within the brain or cannot kill the persister forms of Borrelia (cysts and round bodies). Thus, this study focused on developing antimicrobial cyclic peptides (AMPs) from a combinatorial phage display library that target phosphatidylcholine of the borrelial cell membrane. Isolated cyclic peptides with anti-Borrelia properties were then fused with the CNS homing peptide developed in this study (designated as O-BBB) to facilitate AMP transport across the blood-brain barrier. Among all O-BBB fused AMPs, Bor-18 had half maximal effective concentration (EC50) 0.83 µM when tested against spirochetal Borrelia. Bor-16, Bor-18, and Bor-26 inhibited the cystic form with EC50 0.83 µM, while Bor-11 had EC50 0.41 µM. Within an hour, all four peptides caused a permeability breach in the borrelial cell membrane, causing depolarization of the membrane. Bor peptides did not inhibit eukaryotic cell metabolism or proliferation, nor did they cause erythrocyte lysis. Peptides were stable in serum, could cross the BBB in-vitro, and remained effective against Borrelia. Cyclic AMPs fused with a CNS homing moiety, the Bor peptides, deserve further investigation for their potential use in neuroborreliosis therapy.


  • Open Access

    Complementarity-Determining Region 3 (CDR3) of the Heavy Chain Only Antibodies: Therapeutic Perspectives

    by Lea Talpašová, Katarína Bhide, Tomáš Maľarik, Mangesh Bhide

    Neuroinfections are difficult and time-consuming to treat. The main bottleneck in therapy is drugs’ inability to enter the central nervous system (CNS) via the blood-brain barrier (BBB). Because the diffusion of conventional antibodies in tissues is limited by their large size (150 kDa), it is necessary to find an antibody fragment that can cross the BBB and treat CNS infections. Camelid heavy chain only antibodies, also known as nanobodies, possess a unique Variable domain of a Heavy chain (VHH). The VHH could be used as an alternative to conventional antibodies and have enormous potential in a wide range of medical and bio-technology fields. The VHH with an average molecular weight of 15 kDa can diffuse nearly four times better in tissues and tumours than common antibodies. A VHH is made up of four framework regions (FR1‒4) and three hypervariable complementarity-determining regions (CDR1‒3), with CDR3 being particularly important in interaction with pathogen epitopes. Experimental results have shown that the CDR3 domain alone can bind to epitopes and may contribute to reduce the size of the antigen-recognizing molecule, allowing it to be used more effectively to diffuse much better in tissues, and as well as to cross the BBB and biodistributed in CNS.

  • Open Access

    Developing a Novel Murine Meningococcal Meningitis Model Using a Capsule-Null Bacterial Strain

    by Viorela-I. Caracoti, Costin-Ș. Caracoti, Diana L. Ancuța, Fabiola Ioniță, Andrei-A. Muntean, Mangesh Bhide, Gabriela L. Popa, Mircea I. Popa, Cristin Coman

    Background: Neisseria meningitidis (meningococcus) is a Gram-negative bacterium that colonises the nasopharynx of about 10% of the healthy human population. Under certain conditions, it spreads into the body, causing infections with high morbidity and mortality rates. Although the capsule is the key virulence factor, unencapsulated strains have proved to possess significant clinical implications as well. Meningococcal meningitis is a primarily human infection, with limited animal models that are dependent on a variety of parameters such as bacterial virulence and mouse strain. In this study, we aimed to develop a murine Neisseria meningitidis meningitis model to be used in the study of various antimicrobial compounds. Method: We used a capsule-deficient Neisseria meningitidis strain that was thoroughly analysed through various methods. The bacterial strain was incubated for 48 h in brain–heart infusion (BHI) broth before being concentrated and injected intracisternally to bypass the blood–brain barrier in CD-1 mice. This prolonged incubation time was a key factor in increasing the virulence of the bacterial strain. A total of three more differently prepared inoculums were tested to further solidify the importance of the protocol (a 24-h incubated inoculum, a diluted inoculum, and an inactivated inoculum). Antibiotic treatment groups were also established. The clinical parameters and number of deaths were recorded over a period of 5 days, and comatose mice with no chance of recovery were euthanised. Results: The bacterial strain was confirmed to have no capsule but was found to harbour a total of 56 genes coding virulence factors, and its antibiotic susceptibility was established. Meningitis was confirmed through positive tissue culture and histological evaluation, where specific lesions were observed, such as perivascular sheaths with inflammatory infiltrate. In the treatment groups, survival rates were significantly higher (up to 81.25% in one of the treatment groups compared to 18.75% in the control group). Conclusion: We managed to successfully develop a cost-efficient murine (using simple CD-1 mice instead of expensive transgenic mice) meningococcal meningitis model using an unencapsulated strain with a novel method of preparation.


  • Open Access

    Effect of an immune challenge and two feed supplements on broiler chicken individual breast muscle protein synthesis rate

    by Jorge Peinado-Izaguerri, Alexander Corbishley, Eduardo Zarzuela, Blanca Pina-Beltrán, Francesca Riva, Dorothy E.F. McKeegan, Maureen Bain, Javier Muñoz, Mangesh Bhide, Mark McLaughlin, et al.


  • Open Access

    Mphages and the Blood-Brain Barrier: A Review

    by Tomáš Maľarik, Katarína Bhide, Lea Talpašová, Mangesh Bhide

    The blood-brain barrier (BBB) is a protective barrier that prevents most substances from entering the brain from the bloodstream, including bacteria and viruses. Unfortunately, this restriction also applies to 99.9 % of therapeutics, posing significant challenges in the treatment of brain diseases. Overcoming this barrier is critical for effective treatment of neurological disorders. Several drug delivery systems are being developed to improve transport of therapeutic agent across the BBB. For example, nanoparticles (liposomes, polymeric nanoparticles, dendrimers), nanocarriers (micelles, nanogels), protein-based delivery (penetrating peptides, exosomes), focused ultrasound, and most recently, a filamentous phage based nanocarriers. Filamentous bacteriophages are viruses that infect bacteria and are not designed to infect eukaryotic cells. Recent evidence suggests that filamentous bacteriophages, such as M13, can cross BBB and enter the central nervous system (CNS). Researchers have been investigating the potential use of M13 as drug carriers, including the delivery of therapeutic agents to the brain. This entails modifying the bacteriophages to carry payloads such as drugs and using them as a delivery system. The BBB’s complexity and the potential risks associated with changing it necessitate careful consideration in the development of such strategies. M13 nanocarrier development is ongoing, and advancements may lead to new therapeutic options for treating infections in the CNS. However, it is important to note that this field is still in its infancy, and more research is needed to assess the feasibility and safety of using modified bacteriophages to cross the BBB. This brief review attempts to compile current research on the potential use of bacteriophages for drug transport across the BBB.